ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of March 28, 2023, ACET stock price declined to $5.89 with 23,891 million shares trading.

ACET has a beta of 1.46, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.11 to the broad based SPY ETF.

ACET has a market cap of $253.00 million. This is considered a Small Cap stock.

Last quarter Adicet Bio reported $0 in Revenue and -$.72 earnings per share. This fell short of revenue expectation by $-12 million and missed earnings estimates by -$.44.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ACET has underperformed the market in the last year with a price return of -65.8% while the SPY ETF lost -11.4%. ACET has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.7% and -23.8%, respectively, while the SPY returned +3.9% and +2.8%, respectively.

ACET support price is $5.62 and resistance is $6.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET stock will trade within this expected range on the day.